查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1521007

动物 API 市场 – 2024 年至 2029 年预测

Veterinary Api Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

动物 API 市场预计将从 2024 年的估计值79.25 亿美元成长到 2029 年的 117.94 亿美元，复合年增长率为 8.28%。

兽医学的进步、宠物拥有量的增加以及对兽医保健产品不断增长的需求是兽药 API（活性药物成分）市场快速增长的驱动力。在治疗动物的各种健康状况时，原料药至关重要。由于动物福利意识的增强、监管支持和技术改进等关键因素，市场正在不断扩大。

市场扩张的进一步驱动力是收养伴同性动物作为家庭成员以及创新替代疗法的开发。动物原料药市场专注于改善动物健康和福利，处于持续创新和发展的有利地位，以满足不断变化的行业需求。

动物原料药市场的驱动因素：

  • 越来越多的宠物主人预计将加强动物 API 市场。

动物保健产品市场，尤其是那些依赖原料药的市场，受到宠物饲养量增加的推动。越来越多的家庭将宠物视为家庭成员，这推动了对药物、注射和治疗的需求。这一趋势推动了对满足不同动物物种医疗保健需求的多样化 API 的需求。兽医学的进步和狗饲主对狗的健康所做的大量投资刺激了 API 开发的创新。

此外，宠物的人性化正在提高尖端医疗保健的标准，并推动兽医原料药市场的成长，以满足饲主不断变化的需求。目前的法律规范营造了有利于体外毒性测试行业扩张的氛围。

根据美国兽医协会的数据，2021年，狗和猫的数量增加，养狗和猫的家庭比例也增加，但每户平均宠物数量减少。新购买的宠物很大一部分来自动物收容所，2020 年，38% 的狗和 40% 的猫来自动物收容所。养狗率从年终的38%提高到2020年的45%。 2016年终宠物狗数量预计将从8,370万隻增加到8,890万隻，增幅9%到16%。 2020年，养猫家庭数量比2016年终增加了26%。宠物猫的数量预计将从五年前的 5,840 万隻增加到去年的 6,190 万隻。

  • 技术进步预计将推动动物原料药市场的成长。

兽用原料药市场是由兽药技术开拓驱动的，例如创新的剂量方法和精准医疗方法。药物基因体学、生物技术和奈米技术的进步使得更精确、更有效的动物用药品的开发成为可能。兽医和宠物饲主的需求不断变化，製造技术的改进正在以更有效率、更高品质的原料药满足他们的需求。这些新兴市场的开拓将支持兽用原料药市场的扩张和创新，不仅有助于生产更安全、更有效的药物，还能改善动物健康。

2022年11月7日，印度领先的动物用药品公司之一、对兽药製剂和原料药有着浓厚兴趣的SeQuent Scientific Limited（SeQuent）收购了印度公司Tineta Pharma Private Limited（Tineta）100%的股份。达成了协议。 SeQuent 将印度定位为战略市场，此次收购预计将显着加速其在该国製剂业务的成长，这将受益于在家牛的更大影响力。收购价格为21.8亿印度卢比，包括优先配发价值6.5亿印度卢比的SeQuent股票和15.3亿印度卢比的现金对价。

  • 宠物多样化预计将推动动物原料药市场的发展。

动物原料药市场是由狗、猫、鸟类和爬虫类等各类宠物的广泛饲主所推动的。这些需求需要广泛的药物治疗。这种需求正在推动特定原料药的製造和创造，为多种动物创造强效药物、疫苗和治疗方法。为此，生产商正在开发新的原料药满足不同动物物种的独特生理和药物需求，推动动物用药品产业的扩张。这种动态情况正在推动持续的研究和开发，以提高兽医 API 的可用性和功效，以支持世界各地各种宠物的健康。

动物 API 市场 – 地理视角

  • 亚太地区预计将大幅成长。

亚太地区动物原料药市场正在显着成长。这一增长是由宠物饲养量增加、对动物健康的更好了解以及对高品质动物用药品的需求不断增长等因素所推动的。该地区蓬勃发展的畜牧业也推动了对动物原料药的需求。市场成长是由政府支持动物健康和福利的计划以及动物用药品研究和开发的进步所推动的。由于中产阶级的扩大和生活水准的提高，亚太地区的动物原料药市场预计将继续强劲开拓。

动物原料药市场的限制因素：

  • 监管问题可能会限制动物 API 市场。

兽用原料药业务的一个关键障碍是确保各地区的监管合规性。 FDA 和 EMA 等监管机构制定了兽用原料药必须遵守的严格品质和安全要求。然而，这些要求因国家而异，给寻求出口的製造商带来了挑战。遵守各种法规会为製造过程带来额外的复杂性，需要彻底的测试、记录，有时还需要重新配製。有效克服这些监管障碍，同时保持产品品质和一致性仍然是动物原料药市场中公司面临的主要挑战。

动物 API 市场的主要发展：

  • 2024 年 1 月 -美国食品药物管理局发布产业指南草案。该指南草案的目的是为动物用药品中使用的活性药物原料药(API) 的生产中的良好生产规范 (GMP) 提供提案。这有助于统一全球标准，对活性原料药和动物用药品原料生产设施进行 GMP 检查。
  • 2023 年 1 月 - 为製药业供应原料的 Ofichem Groep 收购了位于莱顿的学名药製造商 InnoGenerics。卫生部也为重新开始提供了40万欧元的担保和额外的15,000欧元的支持。 InnoGenerics 生产治疗多种疾病的非处方药，包括癫痫、糖尿病、心臟病和忧郁症。该公司每年生产超过 30 亿片药片。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章动物原料药市场：依产品类型

  • 介绍
  • 驱虫药
    • 市场趋势和机会
    • 成长前景
  • 抗感染
    • 市场趋势和机会
    • 成长前景
  • 疫苗
    • 市场趋势和机会
    • 成长前景
  • NSAIDs
    • 市场趋势和机会
    • 成长前景
  • 其他的
    • 市场趋势和机会
    • 成长前景

第六章动物原料药市场：依服务类型

  • 介绍
  • 公司内部
    • 市场趋势和机会
    • 成长前景
  • 合约外包
    • 市场趋势和机会
    • 成长前景
    • 合约开发
    • 契约製造

第七章动物原料药市场：依合成类型

  • 介绍
  • 基于 OMICS 化学的 API
    • 市场趋势和机会
    • 成长前景
  • 生物原料药
    • 市场趋势和机会
    • 成长前景
  • 高效能 API (HPAPI)
    • 市场趋势和机会
    • 成长前景

第八章动物原料药市场：依途径

  • 介绍
  • 口服
    • 市场趋势和机会
    • 成长前景
  • 注射
    • 市场趋势和机会
    • 成长前景
  • 局部的
    • 市场趋势和机会
    • 成长前景
  • 其他的
    • 市场趋势和机会
    • 成长前景

第九章动物原料药市场：依地区

  • 介绍
  • 北美洲
    • 依产品类型
    • 按服务类型
    • 依成分类型
    • 依给药途径
    • 按国家/地区
  • 南美洲
    • 依产品类型
    • 按服务类型
    • 依成分类型
    • 依给药途径
    • 按国家/地区
  • 欧洲
    • 依产品类型
    • 按服务类型
    • 依成分类型
    • 依给药途径
    • 按国家/地区
  • 中东/非洲
    • 依产品类型
    • 按服务类型
    • 依成分类型
    • 依给药途径
    • 按国家/地区
  • 亚太地区
    • 依产品类型
    • 按服务类型
    • 依成分类型
    • 依给药途径
    • 按国家/地区

第十章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章 公司简介

  • Sequent Scientific Ltd.（Alivira Animal Health Limited）
  • Stanley Black & Decker（Excel Industries Limited）
  • Ofichem Group
  • Menadiona
  • SUANFARMA
  • NGL Fine-Chem Ltd.
  • FIS-Fabbrica Italiana Sintetici SpA
  • Sidhiv Pharma
  • Chempro Pharma Private Limited
  • AMGIS Lifescience Ltd
简介目录
Product Code: KSI061616896

The Veterinary API market is projected to grow at a CAGR of 8.28% from estimated value of US$7.925 billion in 2024 to US$11.794 billion in 2029.

Advances in veterinary medicine, growing pet ownership, and the growing need for animal healthcare products are driving the veterinary API (Active Pharmaceutical Ingredient) market's rapid rise. When creating treatments for a range of animal health conditions, APIs are essential. The market is expanding due to important factors such as increased awareness about animal welfare, regulatory backing, and technology improvements.

Further driving market expansion are the introduction of companion animals as family members and the development of innovative therapeutic alternatives. With an emphasis on improving animal health and wellbeing, the veterinary API market is well-positioned for ongoing innovation and development to satisfy changing industry demands.

Veterinary API Market Drivers:

  • Increasing pet ownership is anticipated to bolster the veterinary API market.

The market for veterinary healthcare products, particularly those that depend on APIs, is driven by an increase in pet ownership. The number of homes adopting pets as family members is increasing, which drives up the demand for drugs, shots, and therapies. This trend increases the necessity for a variety of APIs catered to the healthcare requirements of different species. Innovation in API development is spurred by veterinary medicine's developments and the significant investment that pet owners make in their dogs' health.

The humanization of pets also raises the bar for cutting-edge medical care, which drives the veterinary API market's growth to satisfy pet owners' changing wants. The current regulatory framework fosters an atmosphere that is conducive to the expansion of the in-vitro toxicity testing industry.

According to the American Veterinary Medical Association, in 2021, the number of dogs and cats increased, as has the proportion of families with dogs or cats, although the average number of pets per household decreased. A significant portion of new pet purchases come from animal shelters; in 2020, 38% of dogs and 40% of cats came from them. Dog ownership increased to 45% of households in 2020 from 38% at the end of 2016. Between 83.7 million and 88.9 million dogs were predicted to be owned as pets at the end of 2016, an increase of 9%-16%. There were 26% more households with cats in 2020 than there were at the end of 2016. The number of pet cats was expected to be between 60 million and 61.9 million last year, up from 58.4 million five years earlier.

  • Technological advancements are expected to drive the veterinary API market growth.

The veterinary API market is being driven by technological developments in veterinary medicine, such as innovative medication delivery methods and precision medicine approaches. Developments in pharmacogenomics, biotechnology, and nanotechnology have made it possible to create veterinary medications that are more precise and efficacious. Veterinarians and pet owners have evolving demands, which are met by APIs produced with more efficiency and quality because of improved manufacturing techniques. These developments not only make it easier to produce safer and more effective drugs, but they also support the expansion and innovation of the veterinary API market, which improves animal health outcomes.

On November 07, 2022, a definitive agreement was reached by SeQuent Scientific Limited (SeQuent), the foremost animal health firm in India with a strong focus on veterinary formulations and APIs, to purchase a 100% share in Tineta Pharma Private Limited (Tineta), an Indian-incorporated company.SeQuent views India as a strategic market, and this acquisition was anticipated to significantly accelerate the growth of the country's formulations business, which benefits from having a larger presence in the cattle market. The transaction was valued at Rs. 218 crores, and the payment for it was made in the form of preferential allotment of SeQuent's equity shares worth Rs. 65 crores and cash consideration of Rs. 153 crores.

  • Diverse pet populations are anticipated to boost the veterinary API market.

The market for veterinary APIs is driven by the wide range of pet owners who own different species of dogs, cats, birds, and reptiles. These needs require a wide range of pharmaceutical treatments. This need drives the creation and manufacturing of specific APIs to create potent drugs, vaccinations, and therapies for many kinds of animals. In response, producers develop novel APIs to cater to the distinct physiological and medicinal needs of various animal species, hence propelling the veterinary pharmaceutical industry expansion. To support the health of different pets around the world, this dynamic landscape encourages ongoing research and development, improving the availability and effectiveness of veterinary APIs.

Veterinary API Market - Geographical Outlook

  • Asia Pacific region is expected to grow significantly.

The veterinary API market in the Asia-Pacific area has grown significantly. This growth has been driven by elements including an increase in pet ownership, a greater understanding of animal health, and a rising need for high-quality veterinary medications. The booming cattle industry in the area has also boosted demand for veterinary APIs. The market is growing because of government programs that support animal health and welfare as well as developments in veterinary medicine research and development. Shortly, the Asia-Pacific veterinary API market is anticipated to maintain its strong development trajectory due to the region's expanding middle class and rising living standards.

Veterinary API Market Restraints:

  • Regulatory concerns can constrain the market for veterinary API.

A significant obstacle in the veterinary API business is making sure regulations are followed in various geographical areas. Regulatory agencies such as the FDA, EMA, and others have strict quality and safety requirements that veterinary APIs must adhere to. However, these requirements might differ greatly between nations, which presents challenges for producers looking to export. Complying with various regulatory regulations introduces additional levels of complexity to the production process, necessitating thorough testing, documentation, and occasionally reformulation. For companies in the veterinary API market, overcoming these regulatory obstacles effectively while preserving product quality and consistency is still a major problem.

Veterinary API Market Key Development:

  • January 2024- U.S. Food and Drug Administration announced a draft guidance for the industry titled. This draft guidance's goal was to offer suggestions for good manufacturing practices (GMPs) in the production of active pharmaceutical ingredients (APIs), used in veterinary pharmaceuticals. It made it easier to harmonize a single set of global standards for GMP inspections of establishments producing APIs and raw ingredients for usage in such goods. Additionally, it gave producers and authorities a framework to guarantee that APIs fulfill the desired standards for quality and purity.
  • January 2023- Ofichem Groep, a provider of raw materials to the pharmaceutical sector, acquired Leiden-based generic drug manufacturer InnoGenerics.The health ministry also backed the relaunch with a €400,000 guarantee and an additional €15,000.InnoGenerics manufactures over-the-counter medications for a variety of illnesses, such as epilepsy, diabetes, heart disease, and depression. The company produced over three billion tablets annually in total.

Market Segmentation:

By Product Type

  • Antiparasitic
  • Anti-infectives
  • Vaccines
  • NSAIDs
  • Others

By Service Type

  • In House
  • Contract Outsourcing
  • Contract Development
  • Contract Manufacturing

By Synthesis Type

  • OMICS Chemical-Based API
  • Biological API
  • Highly Potent API (HPAPI)

By Route of administration

  • Oral
  • Injectable
  • Topical
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. VETERINARY API MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Antiparasitic
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
  • 5.3. Anti-infectives
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects
  • 5.4. Vaccines
    • 5.4.1. Market Trends and Opportunities
    • 5.4.2. Growth Prospects
  • 5.5. NSAIDs
    • 5.5.1. Market Trends and Opportunities
    • 5.5.2. Growth Prospects
  • 5.6. Others
    • 5.6.1. Market Trends and Opportunities
    • 5.6.2. Growth Prospects

6. VETERINARY API MARKET BY SERVICE TYPE

  • 6.1. Introduction
  • 6.2. In House
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
  • 6.3. Contract Outsourcing
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects
    • 6.3.3. Contract Development
    • 6.3.4. Contract Manufacturing

7. VETERINARY API MARKET BY SYNTHESIS TYPE

  • 7.1. Introduction
  • 7.2. OMICS Chemical Based API
    • 7.2.1. Market Trends and Opportunities
    • 7.2.2. Growth Prospects
  • 7.3. Biological API
    • 7.3.1. Market Trends and Opportunities
    • 7.3.2. Growth Prospects
  • 7.4. Highly Potent API (HPAPI)
    • 7.4.1. Market Trends and Opportunities
    • 7.4.2. Growth Prospects

8. VETERINARY API MARKET BY ROUTE OF ADMINISTRATION

  • 8.1. Introduction
  • 8.2. Oral
    • 8.2.1. Market Trends and Opportunities
    • 8.2.2. Growth Prospects
  • 8.3. Injectable
    • 8.3.1. Market Trends and Opportunities
    • 8.3.2. Growth Prospects
  • 8.4. Topical
    • 8.4.1. Market Trends and Opportunities
    • 8.4.2. Growth Prospects
  • 8.5. Others
    • 8.5.1. Market Trends and Opportunities
    • 8.5.2. Growth Prospects

9. VETERINARY API MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product Type
    • 9.2.2. By Service Type
    • 9.2.3. By Synthesis Type
    • 9.2.4. By Route of Administration
    • 9.2.5. By Country
      • 9.2.5.1. United States
        • 9.2.5.1.1. Market Trends and Opportunities
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Trends and Opportunities
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Trends and Opportunities
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Product Type
    • 9.3.2. By Service Type
    • 9.3.3. By Synthesis Type
    • 9.3.4. By Route of Administration
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Trends and Opportunities
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Trends and Opportunities
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Trends and Opportunities
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Product Type
    • 9.4.2. By Service Type
    • 9.4.3. By Synthesis Type
    • 9.4.4. By Route of Administration
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
        • 9.4.5.1.1. Market Trends and Opportunities
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. Germany
        • 9.4.5.2.1. Market Trends and Opportunities
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. France
        • 9.4.5.3.1. Market Trends and Opportunities
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Italy
        • 9.4.5.4.1. Market Trends and Opportunities
        • 9.4.5.4.2. Growth Prospects
      • 9.4.5.5. Spain
        • 9.4.5.5.1. Market Trends and Opportunities
        • 9.4.5.5.2. Growth Prospects
      • 9.4.5.6. Others
        • 9.4.5.6.1. Market Trends and Opportunities
        • 9.4.5.6.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Product Type
    • 9.5.2. By Service Type
    • 9.5.3. By Synthesis Type
    • 9.5.4. By Route of Administration
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Trends and Opportunities
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. UAE
        • 9.5.5.2.1. Market Trends and Opportunities
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Others
        • 9.5.5.3.1. Market Trends and Opportunities
        • 9.5.5.3.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Product Type
    • 9.6.2. By Service Type
    • 9.6.3. By Synthesis Type
    • 9.6.4. By Route of Administration
    • 9.6.5. By Country
      • 9.6.5.1. Japan
        • 9.6.5.1.1. Market Trends and Opportunities
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. China
        • 9.6.5.2.1. Market Trends and Opportunities
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. India
        • 9.6.5.3.1. Market Trends and Opportunities
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Trends and Opportunities
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Taiwan
        • 9.6.5.5.1. Market Trends and Opportunities
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Thailand
        • 9.6.5.6.1. Market Trends and Opportunities
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Indonesia
        • 9.6.5.7.1. Market Trends and Opportunities
        • 9.6.5.7.2. Growth Prospects
      • 9.6.5.8. Others
        • 9.6.5.8.1. Market Trends and Opportunities
        • 9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Sequent Scientific Ltd. (Alivira Animal Health Limited)
  • 11.2. Stanley Black & Decker (Excel Industries Limited)
  • 11.3. Ofichem Group
  • 11.4. Menadiona
  • 11.5. SUANFARMA
  • 11.6. NGL Fine-Chem Ltd.
  • 11.7. FIS - Fabbrica Italiana Sintetici S.p.A.
  • 11.8. Sidhiv Pharma
  • 11.9. Chempro Pharma Private Limited
  • 11.10. AMGIS Lifescience Ltd